Showing 59 results
- Media Library /
- Media Library /
- Media Release /Patients with episodic migraine taking erenumab reported significant and meaningful benefits over six months, with reduced migraine days and acute medication use Fifty percent of patients…
- Media Release /LIBERTY is the first migraine prevention trial of its kind conducted specifically in patients who have tried multiple therapies without success, and are in need of additional treatment options…
- Media Release /Real-world evidence supports benefits seen in Aimovig clinical trials Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine Post-hoc…
- Media Release /Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment Migraine is a leading cause of disability,…
- Media Release /ARISE, first pivotal Phase III study of AMG 334 (erenumab) in episodic migraine prevention, met primary endpoint, showing a statistically significant reduction in monthly migraine days vs placebo…
- Media Release /STRIVE, the first six-month placebo-controlled study of AMG 334 (erenumab) in migraine, met the primary endpoint, showing a statistically significant reduction in monthly migraine days versus…
- Media Release /After long-term Aimovig (erenumab) treatment, two-thirds of chronic migraine patients converted to episodic migraine, experiencing 11 fewer migraine days per month on average Separate study…
- Media Release /Data from LIBERTY demonstrated sustained efficacy of Aimovig (erenumab) 140 mg in reducing monthly migraine days (MMD) at 13-24 weeks in episodic migraine patients with 2-4 prior preventive…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- › Next page